PHARMACEUTICAL COMPOSITION AND COMPOSITION FOR SCREENING THERAPEUTICS TO PREVENTING AND TREATING OF beta;-AMYLOID ACCUMULATION IN BRAIN COMPRISING GCP-II(GLUTAMATE CARBOXYPEPTIDASE-II) AS AN ACTIVE INGREDIENT, METHOD FOR SCREENING USING SAID COMPOSITION

摘要

A composition comprising glutamate carboxypeptidase-II(GCP-II) is provided to decompose a monomer, an oligomer form, a soluble, a non-soluble or an aggregated form of beta-amyloid(Abeta) so as to prevent the accumulation of the Abeta in brain, thereby being used for treating Alzheimer's disease and Down's syndrome. The pharmaceutical composition for preventing and treating Abeta accumulation in brain comprises GCP-II protein as an effective ingredient, where the GCP-II protein includes an amino acid sequence described as SEQ ID : NO. 2. The composition for screening an agent for preventing and treating Abeta accumulation in brain comprises a human GCP-II gene. The method for screening an agent for preventing and treating Abeta accumulation in brain comprises the steps of: (a) contacting the composition for screening the prophylactic and therapeutic agent for Abeta accumulation in brain with a subject material to be tested; and (b) identifying the reaction of the step(a) to determine whether the subject material shows the activity of increasing or inhibiting the expression of the gene.